BindingDB Entry 50013535: A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.

Name: BindingDB Entry 50013535: A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
Creator: BindingDB
Keywords: ADAM17, Bone morphogenetic protein 1, Collagenase, Matrix metalloproteinase-1 (MMP1), Matrix metalloproteinase-14 (MMP14), Matrix metalloproteinase-7 (MMP7), and Stromelysin-1, Pfizer Global Research and Development, Affinity, 3. Good health

Research datakeyboard_double_arrow_right Dataset 01 Jan 2009 English Publisher:BindingDB

Authors: BindingDB;

doi: 10.7270/q24f1q3r

BindingDB Entry 50013535: A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.

- Summary
- Subjects
- Related research
  (22)
- Metrics

tips_and_updates
Recommended

Abstract

Small molecule binding data for protein ADAM17, Bone morphogenetic protein 1, Collagenase, Matrix metalloproteinase-1 (MMP1), Matrix metalloproteinase-14 (MMP14), Matrix metalloproteinase-7 (MMP7), and Stromelysin-1, Uniprot P03956, P08253, P08254, P09237, P13497, P14780, P45452, P50281, and P78536

Keywords

ADAM17, Bone morphogenetic protein 1, Collagenase, Matrix metalloproteinase-1 (MMP1), Matrix metalloproteinase-14 (MMP14), Matrix metalloproteinase-7 (MMP7), and Stromelysin-1, Pfizer Global Research and Development, Affinity

22 Research products, page 1 of 3

BindingDB Entry 50036953: Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
2012IsAmongTopNSimilarDocuments
BindingDB Entry 50032827: TBA
2011IsAmongTopNSimilarDocuments
A Potent, Selective Inhibitor of Matrix Metalloproteinase-3 for the Topical Treatment of Chronic Dermal Ulcers
2003IsDerivedFrom
BindingDB Entry 50042964: Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.
2014IsAmongTopNSimilarDocuments
BindingDB Entry 50016544: Identification of potent and selective MMP-13 inhibitors.
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50030219: Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
2010IsAmongTopNSimilarDocuments
BindingDB Entry 50009811: Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.
2021IsAmongTopNSimilarDocuments
BindingDB Entry 50037150: Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
2012IsAmongTopNSimilarDocuments
BindingDB Entry 50020447: Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50017459: Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
2009IsAmongTopNSimilarDocuments

chevron_left
1
2
3
chevron_right

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average